These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 33972574)

  • 1. Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors.
    Caldwell C; Rottman JB; Paces W; Bueche E; Reitsma S; Gibb J; Adisetiyo V; Haas MS; Heath H; Newman W; Baum J; Gianani R; Kagey MH
    Sci Rep; 2021 May; 11(1):9920. PubMed ID: 33972574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HER2 in situ hybridization in gastric and gastroesophageal adenocarcinoma: comparison of automated dual ISH to FISH.
    Grin A; Brezden-Masley C; Bauer S; Streutker CJ
    Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):561-6. PubMed ID: 23455182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Efficacy, and Biomarker Results from a Phase Ib Study of the Anti-DKK1 Antibody DKN-01 in Combination with Pembrolizumab in Advanced Esophagogastric Cancers.
    Klempner SJ; Bendell JC; Villaflor VM; Tenner LL; Stein SM; Rottman JB; Naik GS; Sirard CA; Kagey MH; Chaney MF; Strickler JH
    Mol Cancer Ther; 2021 Nov; 20(11):2240-2249. PubMed ID: 34482288
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma.
    Hjortland GO; Meza-Zepeda LA; Beiske K; Ree AH; Tveito S; Hoifodt H; Bohler PJ; Hole KH; Myklebost O; Fodstad O; Smeland S; Hovig E
    BMC Cancer; 2011 Oct; 11():455. PubMed ID: 22014070
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DKK1 is a predictive biomarker for response to DKN-01: Results of a phase 2 basket study in women with recurrent endometrial carcinoma.
    Arend R; Dholakia J; Castro C; Matulonis U; Hamilton E; Jackson CG; LyBarger K; Goodman HM; Duska LR; Mahdi H; ElNaggar AC; Kagey MH; Liu A; Piper D; Barroilhet LM; Bradley W; Sachdev J; Sirard CA; O'Malley DM; Birrer M
    Gynecol Oncol; 2023 May; 172():82-91. PubMed ID: 37001446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Expression of Human Epidermal Growth Factor Receptor 2 (HER2) in Gastric and Gastroesophageal Junction Adenocarcinoma Using IHC and Dual-ISH.
    Dominguez C; Rosa M; George TB; Pimiento J; Lauwers GY; Coppola D
    Anticancer Res; 2018 Jan; 38(1):367-372. PubMed ID: 29277796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HER2 Genetic Heterogeneity in Gastric Cancer: Evaluation According to the College of American Pathologists Breast Cancer Criteria.
    Treacy AD; Karamchandani JR; Streutker CJ; Grin A
    Appl Immunohistochem Mol Morphol; 2015 Oct; 23(9):628-32. PubMed ID: 25611242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early miR-223 Upregulation in Gastroesophageal Carcinogenesis.
    Fassan M; Saraggi D; Balsamo L; Realdon S; Scarpa M; Castoro C; Coati I; Salmaso R; Farinati F; Guzzardo V; Arcidiacono D; Munari G; Gasparini P; Veronese N; Luchini C; Valeri N; Rugge M
    Am J Clin Pathol; 2017 Mar; 147(3):301-308. PubMed ID: 28395057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current molecular biomarkers evaluation in gastric/gastroesophageal junction adenocarcinoma: pathologist does matter.
    Businello G; Angerilli V; Lonardi S; Bergamo F; Valmasoni M; Farinati F; Savarino E; Spolverato G; Fassan M
    Updates Surg; 2023 Feb; 75(2):291-303. PubMed ID: 35834132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study.
    Shah MA; Starodub A; Sharma S; Berlin J; Patel M; Wainberg ZA; Chaves J; Gordon M; Windsor K; Brachmann CB; Huang X; Vosganian G; Maltzman JD; Smith V; Silverman JA; Lenz HJ; Bendell JC
    Clin Cancer Res; 2018 Aug; 24(16):3829-3837. PubMed ID: 29691300
    [No Abstract]   [Full Text] [Related]  

  • 11. NeoFLOT: Multicenter phase II study of perioperative chemotherapy in resectable adenocarcinoma of the gastroesophageal junction or gastric adenocarcinoma-Very good response predominantly in patients with intestinal type tumors.
    Schulz C; Kullmann F; Kunzmann V; Fuchs M; Geissler M; Vehling-Kaiser U; Stauder H; Wein A; Al-Batran SE; Kubin T; Schäfer C; Stintzing S; Giessen C; Modest DP; Ridwelski K; Heinemann V
    Int J Cancer; 2015 Aug; 137(3):678-85. PubMed ID: 25530271
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathologic features and treatment outcomes of patients with human epidermal growth factor receptor 2-positive adenocarcinoma of the esophagus and gastroesophageal junction.
    Phillips BE; Tubbs RR; Rice TW; Rybicki LA; Plesec T; Rodriguez CP; Videtic GM; Saxton JP; Ives DI; Adelstein DJ
    Dis Esophagus; 2013 Apr; 26(3):299-304. PubMed ID: 22676551
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Digital Image Analysis of HER2 Immunostained Gastric and Gastroesophageal Junction Adenocarcinomas.
    Nielsen SL; Nielsen S; Vyberg M
    Appl Immunohistochem Mol Morphol; 2017; 25(5):320-328. PubMed ID: 27801737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.
    Shah MA; Ramanathan RK; Ilson DH; Levnor A; D'Adamo D; O'Reilly E; Tse A; Trocola R; Schwartz L; Capanu M; Schwartz GK; Kelsen DP
    J Clin Oncol; 2006 Nov; 24(33):5201-6. PubMed ID: 17114652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
    Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
    Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HER2 Heterogeneity in Gastroesophageal Cancer Detected by Testing Biopsy and Resection Specimens.
    Fazlollahi L; Remotti HE; Iuga A; Yang HM; Lagana SM; Sepulveda AR
    Arch Pathol Lab Med; 2018 Apr; 142(4):516-522. PubMed ID: 28782986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients.
    Fuse N; Kuboki Y; Kuwata T; Nishina T; Kadowaki S; Shinozaki E; Machida N; Yuki S; Ooki A; Kajiura S; Kimura T; Yamanaka T; Shitara K; Nagatsuma AK; Yoshino T; Ochiai A; Ohtsu A
    Gastric Cancer; 2016 Jan; 19(1):183-91. PubMed ID: 25682441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough.
    Weinberg BA; Xiu J; Hwang JJ; Shields AF; Salem ME; Marshall JL
    Oncologist; 2018 Oct; 23(10):1171-1177. PubMed ID: 29703766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and Future Biomarkers in Esophagogastric Adenocarcinoma.
    Sappenfield R; Mehlhaff E; Miller D; Ebben JE; Uboha NV
    J Gastrointest Cancer; 2024 Jun; 55(2):549-558. PubMed ID: 38280174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.